These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
233 related articles for article (PubMed ID: 31775017)
1. Allergen-specific IgE levels and the ability of IgE-allergen complexes to cross-link determine the extent of CD23-mediated T-cell activation. Villazala-Merino S; Rodriguez-Dominguez A; Stanek V; Campion NJ; Gattinger P; Hofer G; Froeschl R; Fae I; Lupinek C; Vrtala S; Breiteneder H; Keller W; Perkmann T; Nakamura R; Pickl WF; Valenta R; Eckl-Dorna J; Niederberger V J Allergy Clin Immunol; 2020 Mar; 145(3):958-967.e5. PubMed ID: 31775017 [TBL] [Abstract][Full Text] [Related]
2. CD23 surface density on B cells is associated with IgE levels and determines IgE-facilitated allergen uptake, as well as activation of allergen-specific T cells. Selb R; Eckl-Dorna J; Neunkirchner A; Schmetterer K; Marth K; Gamper J; Jahn-Schmid B; Pickl WF; Valenta R; Niederberger V J Allergy Clin Immunol; 2017 Jan; 139(1):290-299.e4. PubMed ID: 27372566 [TBL] [Abstract][Full Text] [Related]
3. Different modes of IgE binding to CD23 revealed with major birch allergen, Bet v 1-specific monoclonal IgE. Reginald K; Eckl-Dorna J; Zafred D; Focke-Tejkl M; Lupinek C; Niederberger V; Keller W; Valenta R Immunol Cell Biol; 2013 Feb; 91(2):167-72. PubMed ID: 23229638 [TBL] [Abstract][Full Text] [Related]
4. Inhibition of CD23-dependent facilitated allergen binding to B cells following vaccination with genetically modified hypoallergenic Bet v 1 molecules. Pree I; Shamji MH; Kimber I; Valenta R; Durham SR; Niederberger V Clin Exp Allergy; 2010 Sep; 40(9):1346-52. PubMed ID: 20604801 [TBL] [Abstract][Full Text] [Related]
5. A nonallergenic birch pollen allergy vaccine consisting of hepatitis PreS-fused Bet v 1 peptides focuses blocking IgG toward IgE epitopes and shifts immune responses to a tolerogenic and Th1 phenotype. Marth K; Breyer I; Focke-Tejkl M; Blatt K; Shamji MH; Layhadi J; Gieras A; Swoboda I; Zafred D; Keller W; Valent P; Durham SR; Valenta R J Immunol; 2013 Apr; 190(7):3068-78. PubMed ID: 23440415 [TBL] [Abstract][Full Text] [Related]
6. A double-blind, placebo-controlled birch allergy vaccination study: inhibition of CD23-mediated serum-immunoglobulin E-facilitated allergen presentation. van Neerven RJ; Arvidsson M; Ipsen H; Sparholt SH; Rak S; Würtzen PA Clin Exp Allergy; 2004 Mar; 34(3):420-8. PubMed ID: 15005736 [TBL] [Abstract][Full Text] [Related]
7. Blocking antibodies induced by specific allergy vaccination prevent the activation of CD4+ T cells by inhibiting serum-IgE-facilitated allergen presentation. van Neerven RJ; Wikborg T; Lund G; Jacobsen B; Brinch-Nielsen A; Arnved J; Ipsen H J Immunol; 1999 Sep; 163(5):2944-52. PubMed ID: 10453043 [TBL] [Abstract][Full Text] [Related]
8. An in vitro model for the allergen-IgE-FcARI interaction. Laffer S; Hogbom E; Adrianson J; Grönlund H; Sillaber C; Valent P; Vangelista L; Kricek F; Kraft D; Valenta R Int Arch Allergy Immunol; 1999; 118(2-4):116-8. PubMed ID: 10224355 [TBL] [Abstract][Full Text] [Related]
9. A double-blind placebo-controlled birch allergy vaccination study II: correlation between inhibition of IgE binding, histamine release and facilitated allergen presentation. Würtzen PA; Lund G; Lund K; Arvidsson M; Rak S; Ipsen H Clin Exp Allergy; 2008 Aug; 38(8):1290-301. PubMed ID: 18510696 [TBL] [Abstract][Full Text] [Related]
10. Human blood basophils do not act as antigen-presenting cells for the major birch pollen allergen Bet v 1. Kitzmüller C; Nagl B; Deifl S; Walterskirchen C; Jahn-Schmid B; Zlabinger GJ; Bohle B Allergy; 2012 May; 67(5):593-600. PubMed ID: 22188598 [TBL] [Abstract][Full Text] [Related]
11. Oral exposure to Mal d 1 affects the immune response in patients with birch pollen allergy. Geroldinger-Simic M; Kinaciyan T; Nagl B; Baumgartner-Durchschlag U; Huber H; Ebner C; Lidholm J; Bartel D; Vieths S; Jahn-Schmid B; Bohle B J Allergy Clin Immunol; 2013 Jan; 131(1):94-102. PubMed ID: 22921871 [TBL] [Abstract][Full Text] [Related]
12. Critical and direct involvement of the CD23 stalk region in IgE binding. Selb R; Eckl-Dorna J; Twaroch TE; Lupinek C; Teufelberger A; Hofer G; Focke-Tejkl M; Gepp B; Linhart B; Breiteneder H; Ellinger A; Keller W; Roux KH; Valenta R; Niederberger V J Allergy Clin Immunol; 2017 Jan; 139(1):281-289.e5. PubMed ID: 27343203 [TBL] [Abstract][Full Text] [Related]
13. The major birch pollen allergen Bet v 1 induces different responses in dendritic cells of birch pollen allergic and healthy individuals. Smole U; Radauer C; Lengger N; Svoboda M; Rigby N; Bublin M; Gaier S; Hoffmann-Sommergruber K; Jensen-Jarolim E; Mechtcheriakova D; Breiteneder H PLoS One; 2015; 10(1):e0117904. PubMed ID: 25635684 [TBL] [Abstract][Full Text] [Related]
14. Vig r 6, the cytokinin-specific binding protein from mung bean (Vigna radiata) sprouts, cross-reacts with Bet v 1-related allergens and binds IgE from birch pollen allergic patients' sera. Guhsl EE; Hofstetter G; Hemmer W; Ebner C; Vieths S; Vogel L; Breiteneder H; Radauer C Mol Nutr Food Res; 2014 Mar; 58(3):625-34. PubMed ID: 23996905 [TBL] [Abstract][Full Text] [Related]
15. Birch pollen immunotherapy results in long-term loss of Bet v 1-specific TH2 responses, transient TR1 activation, and synthesis of IgE-blocking antibodies. Möbs C; Ipsen H; Mayer L; Slotosch C; Petersen A; Würtzen PA; Hertl M; Pfützner W J Allergy Clin Immunol; 2012 Nov; 130(5):1108-1116.e6. PubMed ID: 23021882 [TBL] [Abstract][Full Text] [Related]
16. Kinetics, cross-reactivity, and specificity of Bet v 1-specific IgG4 antibodies induced by immunotherapy with birch pollen. Subbarayal B; Schiller D; Möbs C; de Jong NW; Ebner C; Reider N; Bartel D; Lidholm J; Pfützner W; Gerth van Wijk R; Vieths S; Bohle B Allergy; 2013 Nov; 68(11):1377-86. PubMed ID: 24053565 [TBL] [Abstract][Full Text] [Related]
17. Mapping of conformational IgE epitopes with peptide-specific monoclonal antibodies reveals simultaneous binding of different IgE antibodies to a surface patch on the major birch pollen allergen, Bet v 1. Gieras A; Cejka P; Blatt K; Focke-Tejkl M; Linhart B; Flicker S; Stoecklinger A; Marth K; Drescher A; Thalhamer J; Valent P; Majdic O; Valenta R J Immunol; 2011 May; 186(9):5333-44. PubMed ID: 21451110 [TBL] [Abstract][Full Text] [Related]
18. A novel role for neutrophils in IgE-mediated allergy: Evidence for antigen presentation in late-phase reactions. Polak D; Hafner C; Briza P; Kitzmüller C; Elbe-Bürger A; Samadi N; Gschwandtner M; Pfützner W; Zlabinger GJ; Jahn-Schmid B; Bohle B J Allergy Clin Immunol; 2019 Mar; 143(3):1143-1152.e4. PubMed ID: 29920351 [TBL] [Abstract][Full Text] [Related]
19. Formation of IgE-Allergen-CD23 Complex Changes in Children Treated with Subcutaneous Immunotherapy for Japanese Cedar Pollinosis. Asaumi T; Sato S; Yanagida N; Matsuhara H; Kobayashi S; Fukano C; Ohashi-Doi K; Ebisawa M Int Arch Allergy Immunol; 2021; 182(3):190-194. PubMed ID: 33032294 [TBL] [Abstract][Full Text] [Related]
20. Intranasal administration of allergen increases specific IgE whereas intranasal omalizumab does not increase serum IgE levels-A pilot study. Eckl-Dorna J; Fröschl R; Lupinek C; Kiss R; Gattinger P; Marth K; Campana R; Mittermann I; Blatt K; Valent P; Selb R; Mayer A; Gangl K; Steiner I; Gamper J; Perkmann T; Zieglmayer P; Gevaert P; Valenta R; Niederberger V Allergy; 2018 May; 73(5):1003-1012. PubMed ID: 29083477 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]